|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||99.99 - 103.50|
|52 Week Range||94.55 - 147.17|
|PE Ratio (TTM)||24.12|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Celgene and Sanofi are the latest big drugmakers willing to pay hefty premiums for acquisitions amid an increasingly scarce roster of companies with promising products.
Juno Therapeutics Inc. and CEO Hans Bishop emailed employees, founders and vendors Monday morning to let them know of the company's $9 billion deal to sell to Celgene Corp. "For many of us this is a surprising development, and I am sure comes with some mixed emotions," he told employees. Celgene i ncreased its investment in Seattle-based Juno last year after the failure of its flagship drug trail .
Celgene has an excellent track record and we expect the company to keep the momentum in the fourth quarter. Investors will also focus on updates on recent acqusitions.
Celgene will buy Juno Therapeutics for $9 billion and French pharma Sanofi will pay $11.6 billion for Bioverativ.
Celgene has gone “all-in” on CAR-T cancer therapies, forking out $9 billion to acquire Juno Therapeutics amid much fanfare. Critics worry this wager may fail to help the biotech giant fill the gaps in its revenue stream.
U.S. stocks advanced on Monday as each of Wall Street's main scored records in the wake of a deal by U.S. senators to end the federal government shutdown. Legislation to renew federal funding to the government cleared a procedural hurdle in the Senate and was expected soon to pass votes in the Senate and House of Representatives, allowing government to re-open through Feb 8.
Celgene will acquire Juno Therapeutics for $9 billion. Sanofi reached a deal Monday to buy hemophilia drugmaker Bioverativ for $11.6 billion, or $105 a share.
Celgene (CELG) is on a shopping spree this year: First, it bought Impact Biomedicines for $1.1 billion at the start of the month, and today it announced that it will buy Juno Therapeutics (JUNO) for $87 a share in cash, or $9 billion. Rumors of a Juno deal leaked last week, so some analysts had already come out in favor of the combination. SunTrust Robinson Humphrey's Yatin Suneja reiterated a Buy rating on the stock, and writes that investors should be excited about the fact that Juno should allow Celgene to stay at the "forefront of cellular therapy," as well as diversify its business away from the myeloma franchise. Suneja also thinks that Celgene paid a fair price for the company.
Juno Therapeutics (NASDAQ:JUNO) shares were skyrocketing as the company has agreed to be acquired by Celgene Corporation (NASDAQ:CELG). The subject of the acquisition is responsible for making some of the most innovative cancer immunotherapy treatments. Celgene will shell out $87 per share for Juno Therapeutics, roughly $87 per share.
U.S. stocks advanced on Monday as each of Wall Street's main indexes touched a record intraday level after U.S. senators struck a deal to end the federal government shutdown. U.S. senators voted to move forward on legislation that would reopen the federal government until Feb. 8. Funding legislation cleared a procedural hurdle in the Senate and was expected to pass a full Senate vote promptly, allowing government to re-open.
Celgene said it agreed to buy Juno Therapeutics for $87 a share in cash, or about $9 billion, in a move that will expand Celgene’s portfolio of blood-cancer drugs.
Celgene announced a $9 billion cash buyout of Juno Therapeutics as it moves to cement its position as a key player in a new range of cancer therapies. Aleksandra Michalska reports.
Jan.22 -- Bloomberg Gadfly columnist Max Nisen discusses Celgene's $9 billion buyout of Juno Therapeutics and Sanofi's $11.6 billion deal for Bioverativ on "Bloomberg Markets." (Nisen is a Bloomberg Gadfly columnist. The opinions expressed are his own.)
"Halftime Report" trader Pete Najarian spots unusual activity in Hanesbrands and Delta. Plus, a trade update on Juno Therapeutics, which is up more than 90% since he saw unusual in the name last month.